Compare Amgen, Inc. (AMGN) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs CarMax, Inc — how do they compare? Amgen, Inc. trades at $416 (market cap $224.14B), while CarMax, Inc trades at $58.22 (market cap $8.26B). The key difference: Amgen, Inc. is far larger — about 27.1× CarMax, Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| AMGN | KMX | |
|---|---|---|
Market Cap | $224.14B | $8.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $62.17 |
52-Week Low | $271.18 | $30.88 |
Enterprise Value | $267.45B | $26.77B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
CarMax (KMX) trades at $58.20, showing modest near-term weakness with a 0.99% daily decline. The stock maintains a bullish technical stance with strong moving average support and trades near key support at $58. Fundamentally, the company reported Q1 2026 earnings beat with $0.34 EPS versus $0.23 expected, though revenue trends show slight contraction from $26.4B in 2025 to projected $26.3B in 2026. Recent positive developments include AI partnership enhancements and strong institutional recognition.
CarMax presents a mixed investment case with technical strength offset by fundamental challenges. The bullish moving average configuration and recent earnings beats provide near-term support, but declining revenue trends and thin 0.84% net margin limit upside potential. Key risks include ongoing fiduciary investigations and competitive pressure in the used car market. Analyst consensus remains cautious with 68.6% hold ratings and $53.09 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
